CCR2 is still a long way off being used as a clinical therapy but as I have hopefully demonstrated, it has significant potential, at least for more research to be done into its uses, even if it never appears as a liscenced treatment. Here is a quick summary table of the current status of drugs that are being tested at the moment. For a wider view on the current status of other potential chemokine therapies visit the review that I adapted this table from, at http://www.jsir.gr.jp/journal/Vol31No1/pdf/03_R2_11.pdf
From what I have gleaned from my research, MLN1202 seems one of the most promising drugs. As I have already described, it is a monoclonal antibody that has actually been tested on humans with significant reduction in C-reactive protein (a biomarker for atherosclerosis). For this reason, it seems plausible that once safety aspects have been assured, this drug has the potential to provide clinical benefit to patients with atherosclerosis disease as it has proven efficacy in humans, not just animal models.
Conclusions
I have aimed to give a comprehensive review on CCR2 blockade and hopefully I have provided enough information on the subject so that you can see the significance of this topic but also so that you can make your own mind up about how useful it is to aim chemokine research towards this specific receptor. Whether I have helped you along the path to becoming a budding scientist or not, I hope you found my blog useful in some way or another!
No comments:
Post a Comment